TOKYO, Nov. 24 (Xinhua) -- Tokyo stocks surged Tuesday morning, with the benchmark Nikkei stock index hitting its highest level in over 29 years after a potential COVID-19 vaccine developed by the University of Oxford and British drugmaker AstraZeneca Plc showed up to 90 percent efficacy in late-stage trials.
The 225-issue Nikkei Stock Average increased 669.27 points, or 2.62 percent, from Friday to its highest intraday level of 26,196.64 since May 14, 1991.
The broader Topix index of all First Section issues on the Tokyo Stock Exchange, meanwhile, rose 38.41 points, or 2.22 percent, at 1,765.80. Japanese markets were closed Monday for a national holiday.
Metal product, securities house and iron and steel issues comprised those that gained the most by the morning break.